NYMOX PHARMACEUTICAL CORP (NYMX) Stock Income Statement
NASDAQ:NYMX - Nasdaq - BSP733981026 - Common Stock - Currency: USD
| TTM (2023-3-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 10.00K | 120.00K | |||
| Cost Of Goods | N/A | N/A | 0.00 | 0.00 | 60.00K | |||
| Gross Profit | N/A | N/A | 0.00 | 0.00 | 60.00K | |||
| Operating Expenses | 2.96M | 6.65M | 12.50M | 11.73M | 13.38M | |||
| Research and Development | 159.00K | 3.77M | 6.66M | 8.11M | 7.37M | |||
| Selling, General, and Administrative Expenses | 2.80M | 2.88M | 5.85M | 3.60M | 6.01M | |||
| Operating Income | -2.96M | -6.65M | -12.50M | -11.72M | -13.33M | |||
| Interest Income/Expense | -27.00K | -37.00K | -33.00K | -20.00K | 160.00K | |||
| Other Income/Expense | N/A | 113.00K | N/A | N/A | 0.00 | |||
| Income Before Taxes | -2.88M | -6.58M | -12.54M | -11.74M | -13.16M | |||
| Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Net Income | -2.88M | -6.58M | -12.54M | -11.74M | -13.16M | |||
| EBITDA | -2.95M | -6.64M | -12.49M | -11.71M | -13.32M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.03 | -0.07 | -0.15 | -0.16 | -0.19 | |||
| Statistics | ||||||||
| Gross Profit Margin | N/A | N/A | N/A | N/A | 50.00% | |||
| Profit Margin | N/A | N/A | N/A | -117400.00% | -10966.67% | |||
| Operating Profit Margin | N/A | N/A | N/A | -117200.00% | -11108.33% | |||
All data in USD